WHAT IS DESCRIBED IS A PROCESS FOR PRODUCING HIGH-PURITY GADOBUTROL IN A PURITY (ACCORDING TO HPLC) OF MORE THAN 99.7 OR 99.8 OR 99.9% AND THE USE FOR PREPARING A PHARMACEUTICAL FORMULATION FOR PARENTERAL ADMINISTRATION. THE PROCESS IS CARRIED OUT USING SPECIFICALLY CONTROLLED CRYSTALLIZATION CONDITIONS. THE MORE RECENT DEVELOPMENTS IN THE FIELD OF THE GADOLINIUM-CONTAINING MR CONTRAST AGENTS (EP 0448191 B1, CA PATENT 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) INCLUDE THE MRT CONTRAST AGENT GADOBUTROL (GADOVIST® 1.0) WHICH HAS BEEN APPROVED FOR A RELATIVELY LONG TIME IN EUROPE AND MORE RECENTLY ALSO IN THE USA UNDER THE NAME GADAVIST®.
